Regulatory Elements, Receptors & Capsids

Achieve targeted and robust gene expression with Ginkgo’s licensable promoters. Our fast-acting muscle promoters surpass MHCK7 in vivo, while our RNA polymerase III promoters deliver greater guide RNA expression than U6. For other targets and applications, our AI-powered design and high-throughput screening can identify promoter candidates tailored to your cell contexts of interest within three months.

Pricing and terms are available upon consultation and will vary based on specific requirements.

Extend RNA lifespan and boost protein production with Ginkgo’s in vivo-validated 3’ UTRs for stability and 5’ UTRs for increased protein expression. For customized applications, leverage our UTR expertise and AI models to design and screen tens of thousands of UTRs, with top UTR candidates for your payload identified in three months.

Pricing and terms are available upon consultation and will vary based on specific requirements.

Elevate your circRNA or multicistronic constructs with our licensable IRESs for enhanced translation versus CBV3, or utilize our custom introns for improved RNA circularization versus Anabaena. These sequences have been selected via metagenomic mining, sequence engineering, and high-throughput screening, and Ginkgo can offer bespoke solutions for further IRES and intron development tailored to your payload and application.

Pricing and terms are available upon consultation and will vary based on specific requirements.

Boost therapeutic efficacy with Ginkgo’s innovative CARs and synthetic immune receptors. Our assets include CAR ICD sequences for increased T cell activation, novel switch receptors for immunosuppression resistance, and synthetic cytokine receptors for STAT3 and STAT5 signaling.

Pricing and terms are available upon consultation and will vary based on specific requirements.

The STRV AAV capsids were engineered to reduce their antigenic footprint, detarget the liver, and support manufacturability. Our licensable capsids include STR47, a pan-tropic capsid validated in NHP for high potency in kidney; STRV84, a cardiac- and CNS-tropic, liver-detargeted capsid validated in multiple animal models; STRV5, a potent CNS transducer; and STRV16, a liver-detargeted capsid with selectivity for skeletal muscle vs. heart. For other targets, consider a screening project with our pre-designed capsid libraries or full capsid-payload optimization.

Pricing and terms are available upon consultation and will vary based on specific requirements.

Our combined offering leverages Ginkgo’s advanced high-throughput screening capabilities with Virica’s proprietary Viral Sensitizers to drive down the costs of AAV manufacturing and provide a unique one-stop solution to our AAV gene therapy manufacturing partners. Improve titer and test scale up with combinatorial designs to identify the optimal conditions for rAAV production in as little as six weeks. (Image courtesy of Virica Biotech)

Pricing and terms are available upon consultation and will vary based on specific requirements.